WO2016090892A1 - 一种治疗糖尿病足的水溶性凝胶 - Google Patents

一种治疗糖尿病足的水溶性凝胶 Download PDF

Info

Publication number
WO2016090892A1
WO2016090892A1 PCT/CN2015/082037 CN2015082037W WO2016090892A1 WO 2016090892 A1 WO2016090892 A1 WO 2016090892A1 CN 2015082037 W CN2015082037 W CN 2015082037W WO 2016090892 A1 WO2016090892 A1 WO 2016090892A1
Authority
WO
WIPO (PCT)
Prior art keywords
water
soluble gel
weight
type
wound
Prior art date
Application number
PCT/CN2015/082037
Other languages
English (en)
French (fr)
Inventor
奚廷斐
杨信诚
赵晓峰
雷小林
Original Assignee
成都新际生物活性胶原开发有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 成都新际生物活性胶原开发有限公司 filed Critical 成都新际生物活性胶原开发有限公司
Publication of WO2016090892A1 publication Critical patent/WO2016090892A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Definitions

  • the invention relates to a water-soluble gel for treating diabetic foot, belonging to the field of natural biomacromolecules.
  • Diabetic foot is a general term for lesions such as foot itching, skin ulcers, and gangrene of the extremities caused by diabetes. It is a foot infection, ulcer, and deep tissue destruction associated with distal nerve abnormalities of the lower extremities and varying degrees of peripheral vascular disease. (According to the definition of WHO). It is a serious complication of diabetes patients, which seriously affects the quality of life of patients.
  • the pathogenesis of diabetic foot is complex, and it is different from general tissue wounds. Under high sugar concentration, tissue healing is relatively difficult, coupled with neuropathy, loss of neurotrophic effect. Perivascular lesions, limited local circulation, is more detrimental to wound healing.
  • the current treatment generally has blood sugar control, debridement, anti-infection, and treatment for severe intervention and amputation in the later stage.
  • Method research has been continuously explored.
  • Diabetic foot is divided into three types according to the main mechanism of pathogenesis: simple ulcer, neurogenic, and angiogenic.
  • Clinical treatment differs according to its different types of treatment, but no matter what kind of treatment, an important mechanism is to use the skin self-repair ability to induce dermal regeneration.
  • new capillary formation and fibroblast and epithelial cell proliferation repair play a major role.
  • collagen fibers around the newborn cells There is a large amount of collagen fibers around the newborn cells, and there is information that collagen has the effect of inducing dermal tissue repair.
  • the price of exogenous collagen is relatively expensive and cannot be widely promoted. How to absorb collagen in the body is also a factor that restricts the external use of collagen.
  • the biological low antigenic active collagen (type I) is a natural biological macromolecule, which is refined from the fresh animal skin (eg, suede, cowhide, pigskin, etc.) that has passed inspection and quarantine.
  • Chinese Patent ZL 201010176321.9 discloses a method for extracting active collagen (type I) from suede, but has not been studied for its application. Therefore, how to apply active collagen (type I) is still in the exploration stage.
  • the present invention aims to provide a new way of solving the treatment of diabetic foot, inducing topical collagen for skin regeneration, shortening the skin healing time, and reducing scar formation as close as possible to the original tissue structure of the skin. Reduce the occurrence of diabetic foot, and the price is low, the patient suffers little, and there is no toxic side effect.
  • a water-soluble gel for treating diabetic foot comprising:
  • the above bio-low antigenic active collagen (type I) is obtained by extracting collagen from fresh animal skin (for example, suede, cowhide, pig skin, etc.), and a specific method such as CN201010176321.9 and The method described in CN201473478U.
  • the above bioactive antigenic active collagen (type I) stock solution obtained by the method is a white, filamentous atelopeptide, wherein the content of the biological low antigenic active collagen (type I) can reach 99.5% or more.
  • the low antigenic active collagen (type I) maintains the spatial structure of the triple helix undisturbed, has a relative molecular mass of about 300 KD, is biologically active, and has low antigenicity.
  • the low antigenic active collagen (type I) has the same molecular weight and structure as human skin and connective tissue, and has homology and compatibility; and under neutral conditions, it can be miscible with water in any proportion in the human body. At body temperature, it can be decomposed into peptides, single peptides, and can be decomposed into amino acids under the action of other enzymes, thus having strong water solubility and degradability.
  • the above diluent is obtained by diluting the extracted stock solution in a certain ratio. Specifically, it may be diluted with deionized water such that the concentration of the biologically low antigenic active collagen (type I) is between 0.1% and 0.5%.
  • concentration calculation can be referred to the method in CN200610021100.8.
  • the amount of the biologically low antigenic active collagen (type I) diluent is determined based on the concentration of the biologically low antigenic active collagen (type I), and specifically, the concentration thereof is preferably from 0.3% to 0.5%.
  • the above-mentioned moisturizer functions to moisturize the wound, and includes, but is not limited to, glycerin; and the amount thereof is preferably 4 to 4.5 parts by weight.
  • the above bactericide acts to inhibit bacterial growth, and includes, but is not limited to, methylparaben, propylparaben; and the amount thereof is preferably 0.1 to 0.5 part by weight, more preferably 0.1 to 0.2 part by weight. .
  • the above auxiliary material serves to form a water-soluble sebum film on the surface of the wound during application, to isolate the wound from the external environment, prevent wound infection, and prevent ultraviolet rays, including but not limited to water-soluble silicone oil.
  • it may be DC193; its amount is preferably 0.1 to 0.8 part by weight, more preferably 0.2 to 0.6 part by weight.
  • the above water-soluble gel comprises the following components:
  • the above water soluble gel comprises the following components:
  • the above water soluble gel comprises the following components:
  • Another object of the present invention is to provide a method for preparing the above water-soluble gel, comprising the steps of:
  • Another object of the present invention is to provide an application of the above water-soluble gel in the preparation of a medicament for treating diabetic foot.
  • the invention has the beneficial effects of imparting biological information possessed by the natural macromolecular active collagen (type I), inducing regeneration and repair of the micro-nerve and micro-vessels of the body tissue, so as to achieve the purpose of recovery of the body.
  • Fig. 1 is a view showing the healing condition of a wound in a rat of Example 4.
  • Figure 2 is a graph showing EGF expression, FGF expression and NGF expression in rat wounds in Example 4.
  • the biological low-antigen active collagen (type I) stock solution was diluted with deionized water to obtain a dilution of the biological low-antigenic active collagen (type I) at a concentration of 0.3%, and 95 g of the diluted solution and 4 g of glycerin, 0.15 g of nicotine were weighed. Potassium methyl ester, 0.05 g of propylparaben was stirred and mixed, and then filtered, and then 0.6 g of water-soluble silicone oil was added and stirred uniformly.
  • the biological low-antigen active collagen (type I) stock solution was diluted with deionized water to obtain a dilution of 0.5% of the biologically low antigenic active collagen (type I), and 90 g of the diluted solution and 4.5 g of glycerin, 0.25 g were weighed. Methylparaben, 0.15 g of propylparaben was stirred and mixed, and then filtered, and then 0.5 g of water-soluble silicone oil was added thereto and stirred uniformly.
  • the biological low-antigen active collagen (type I) stock solution was diluted with deionized water to obtain a dilution of bio-low antigenic active collagen (type I) at a concentration of 0.4%, and 94 g of the diluted solution and 4.0 g of glycerin, 0.15 g were weighed.
  • Methylparaben, 0.05 g of propylparaben was stirred and mixed, and then filtered, and then 0.55 g of water-soluble silicone oil was added and stirred uniformly.
  • the wound healing condition of the rats in Example 4 is shown in Fig. 1.
  • the left and right wounds of the same rat were each about 3.14 cm 2 ; wherein a was randomly selected after 8 days of application to examine the healing of the wound, and the wound healing was 60%. b was randomly selected after 12 days of application to check the healing of the wound, and the wound was healed by 90%; c was randomly selected after 15 days of application to check the healing of the wound, and the wound was basically healed.
  • EGF, FGF expression and NGF expression in the wounds of the rats in Example 4 are shown in Fig. 2; wherein E is the expression of EGF on the uncoated wound after 12 days; F is the expression of EGF on the wound after 12 days; G is not after 12 days. FGF expression in coated wounds; H was coated with collagen FGF expression after 12 days; I was uncoated WGF expression after 12 days; J was coated with collagen NGF expression after 12 days.
  • the same rat was coated with active collagen (type I) water-soluble gel on the back side. Each time the thickness of the wound was covered with the wound, the dosage was about 4 ml, and the other time, the blank control was used, and the dressing was changed 3 times a day.
  • active collagen type I
  • the back side of the same rat was coated with active collagen (type I) water-soluble gel. Each time the thickness of the wound was covered with the wound, the dosage was about 4 ml, and the other time, the blank control was used, and the dressing was changed 6 times a day. Ensure that the wound is always covered with collagen.
  • active collagen type I

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

提供了一种治疗糖尿病足的水溶性凝胶，包括：90-95重量份的生物低抗原性活性胶原(Ⅰ型)稀释液，3-5重量份滋润剂，0.1-1重量份杀菌剂，0.1-1重量份辅料。该水溶性凝胶赋予天然大分子活性胶原(Ⅰ型)具有的生物信息，诱导机体组织的微神经，微血管的再生修复，以达到机体恢复的目的。

Description

一种治疗糖尿病足的水溶性凝胶 技术领域
本发明涉及一种治疗糖尿病足的水溶性凝胶，属于天然生物大分子医疗器械领域。
技术背景
糖尿病足(diabetic foot)是糖尿病引起的足部瘙痒、皮肤溃疡、肢端坏疽等病变的总称.是与下肢远端神经异常和不同程度的周围血管病变相关的足部感染、溃疡和深层组织破坏(根据WHO的定义)。是糖尿病患者严重的并发症，严重影响病人的生活质量，糖尿病足发病机理复杂，和一般组织创面有所不同，在高糖浓度下，组织愈合相对困难，再加上神经病变，失去神经营养作用，血管周围病变，局部循环受限，更加不利于伤口愈合。
目前的治疗一般有控制血糖、清创、抗感染，对于后期严重行介入、手术截肢等治疗，但是由于治疗效果欠佳，费用较大，给病人带来不小痛苦，因此对于糖尿病足治疗新方法研究一直不断探索。
糖尿病足根据致病主要机理分为三型：单纯溃疡性、神经源性、血管源性。临床治疗根据其不同类型区别治疗，但是无论何种治疗一项重要机理就是利用皮肤自我修复能力进行诱导真皮再生，在诱导过程中，新毛细血管形成及成纤维细胞、上皮细胞增生修复起主要作用，而在新生细胞周围有大量胶原纤维，并有资料表明：胶原蛋白具有诱导真皮组织修复作用。但是一般外源胶原蛋白价格较为昂贵，不能广泛推广，外用胶原蛋白如何被体内吸收也是制约胶原蛋白外用的因素，从异体提取胶原蛋白还存在抗原-抗体反应风险。
生物低抗原性活性胶原(Ⅰ型)是天然生物大分子，是从检验检疫合格的鲜动物皮(例如：驴皮，牛皮，猪皮等)中精制提取的。中国专利ZL 201010176321.9公开了一种从驴皮中提取活性胶原(Ⅰ型)的方法，但并未对其应用展开研究。因此，对于活性胶原(Ⅰ型)如何应用仍处于摸索阶段。
发明内容
针对上述技术问题，本发明目的在于提供一种解决糖尿病足治疗的新的方式，诱导皮肤再生的外用胶原蛋白，使皮肤愈合时间明显缩短，并减少瘢痕形成，尽可能接近皮肤原有组织结构，减少糖尿病足的发生，并且价格低廉、病人痛苦小、无毒副作用。
本发明的上述目的是通过如下技术方案实现的：一种治疗糖尿病足的水溶性凝胶，包括：
Figure PCTCN2015082037-appb-000001
Figure PCTCN2015082037-appb-000002
在本发明中，上述生物低抗原性活性胶原(Ⅰ型)是通过从新鲜的动物皮(例如：驴皮，牛皮，猪皮等)中提取得到的胶原，具体方法可以采用如CN201010176321.9和CN201473478U中所述的方法。采用该方法得到的上述生物低抗原性活性胶原(Ⅰ型)原液是一种白色，丝状的无端肽，其中生物低抗原性活性胶原(Ⅰ型)含量可以达到99.5％以上。经发明人研究发现，该低抗原性活性胶原(Ⅰ型)保持三股螺旋的空间结构未受破坏，相对分子质量约300KD，具有生物活性；并且具有低抗原性的特点。研究还发现，该低抗原性活性胶原(Ⅰ型)分子量和结构与人体皮肤及结缔组织相同，具有同源性和相容性；并且其中中性条件下能够与水以任意比例互溶，在人体体温下，能够分解成多肽，单肽，又在其它酶的作用下能够分解成氨基酸，因而具有很强的水溶性和降解性。
上述稀释液是通过将提取得到的原液以一定比例稀释后得到的。具体而言，可以采用去离子水进行稀释，使得其中生物低抗原性活性胶原(Ⅰ型)的浓度在0.1％-0.5％。上述浓度计算可参考CN200610021100.8中的方法。在本发明中，生物低抗原性活性胶原(Ⅰ型)稀释液用量是根据生物低抗原性活性胶原(Ⅰ型)的浓度来确定的，具体而言，优选其浓度在0.3％-0.5％。
在本发明中，上述滋润剂中起到滋润伤口的作用，其包括但不限于是甘油；其用量优选4-4.5重量份。
在本发明中，上述杀菌剂起到抑制细菌生长的作用，其包括但不限于是尼泊金甲酯，尼泊金丙酯；其用量优选0.1-0.5重量份，更优选0.1-0.2重量份。
在本发明中，上述辅料起到在施用时，在伤口表面形成一层水溶性皮脂膜，使得伤口与外界环境隔绝，防止伤口感染，以及防止紫外线的作用，其包括但不限于水溶性硅油，例如可以是DC193；其用量优选0.1-0.8重量份，更优选0.2-0.6重量份。
在本发明的一个具体实例中，上述水溶性凝胶包括如下组分：
Figure PCTCN2015082037-appb-000003
在本发明另一个具体实例中，上述水溶性凝胶包括如下组分：
Figure PCTCN2015082037-appb-000004
在本发明另一个具体实例中，上述水溶性凝胶包括如下组分：
Figure PCTCN2015082037-appb-000005
本发明的另一目的是提供一种上述水溶性凝胶的制备方法，包括如下步骤：
1)将生物低抗原性活性胶原(Ⅰ型)原液用水稀释；
2)将滋润剂和杀菌剂与步骤1得到的稀释液混合搅拌；
3)过滤；
4)将辅料与步骤3得到的物料混合，搅拌均匀。
在上述制备方法中，应在无菌环境下进行。
本发明的另一目的是提供一种上述水溶性凝胶在制备治疗糖尿病足的药物中的应用。
本发明的有益效果在于：赋予天然大分子活性胶原(Ⅰ型)具有的生物信息，诱导机体组织的微神经，微血管的再生修复，以达到机体恢复的目的。
附图说明
图1为是实施例4中大鼠创面愈合情况图。
图2为实施例4中大鼠创面EGF表达、FGF表达和NGF表达图。
具体实施方式
实施例1
取生物低抗原性活性胶原(Ⅰ型)原液以去离子水稀释，得到生物低抗原性活性胶原(Ⅰ型)的浓度为0.3％的稀释液，称取95g稀释液与4g甘油，0.15g尼泊金甲酯，0.05g尼泊金丙酯搅拌混合后过滤，然后加入0.6g水溶性硅油搅拌均匀。
实施例2
取生物低抗原性活性胶原(Ⅰ型)原液以去离子水稀释，得到生物低抗原性活性胶原(Ⅰ型)的浓度为0.5％的稀释液，称取90g稀释液与4.5g甘油，0.25g尼泊金甲酯，0.15g尼泊金丙酯搅拌混合后过滤，然后加入0.5g水溶性硅油搅拌均匀。
实施例3
取生物低抗原性活性胶原(Ⅰ型)原液以去离子水稀释，得到生物低抗原性活性胶原(Ⅰ型)的浓度为0.4％的稀释液，称取94g稀释液与4.0g甘油，0.15g尼泊金甲酯，0.05g尼泊金丙酯搅拌混合后过滤，然后加入0.55g水溶性硅油搅拌均匀。
实施例4
1、取10只平均体重为220g的糖尿病雄性大鼠，背部剃毛后消毒，用打孔器于大鼠背部脊柱两侧分别各打一孔(直径2cm)深及筋膜层。
2、采用同体对照，同一只大鼠背部一侧涂有活性胶原(Ⅰ型)水溶性凝胶，每次用量只覆盖创面薄薄一层，用量大约1ml，另一次采用空白对照，一天换药3次。
3、观察8天、12天、15天、创面愈合情况、创面肉芽组织生长情况，病理切片观察创面炎症、成纤维细胞数量。采用免疫组化检测涂药组和对照组的表皮生长因子、成纤维细胞生长因子以及神经生长因子。
实施例4中大鼠创面愈合情况参见图1所示，同一只大鼠的左右创面各约3.14cm2；其中a为涂药8天后随机选取一只大鼠检查创面愈合情况，创面愈合60％；b为涂药12天后随机选取一只大鼠检查创面愈合情况，创面愈合90％；c为涂药15天后随机选取一只大鼠检查创面愈合情况，创面基本痊愈。
实施例4中大鼠创面EGF表达、FGF表达和NGF表达参见图2所示；其中E为12天后未涂药创面EGF表达；F为12天后涂有胶原蛋白创面EGF表达；G为12天后未涂药创面FGF表达；H为12天后涂有胶原蛋白创面FGF表达；I为12天后未涂药创面NGF表达；J为12天后涂有胶原蛋白创面NGF表达。
实施例5
1、取10只平均体重为220g的糖尿病雄性大鼠，背部剃毛后消毒，用打孔器于大鼠背部脊柱两侧分别各打一孔(直径2cm)深及筋膜层。
2、采用同体对照，同一只大鼠背部一侧涂有活性胶原(Ⅰ型)水溶性凝胶，每次用量厚厚覆盖创面，用量大约4ml，另一次采用空白对照，一天换药3次。
3、观察8天、12天、15天、创面愈合情况、病理切片观察创面炎症、成纤维细胞数量。采用免疫组化检测涂药组和对照组的表皮生长因子、成纤维细胞生长因子以及神经生长 因子。
实施例6
1、取10只平均体重为220g的糖尿病雄性大鼠，背部剃毛后消毒，用打孔器于大鼠背部脊柱两侧分别各打一孔(直径2cm)深及筋膜层。
2、采用同体对照，同一只大鼠背部一侧涂有活性胶原(Ⅰ型)水溶性凝胶，每次用量只覆盖创面薄薄一层，用量大约1ml，另一次采用空白对照，一天换药6次，保证创面始终有胶原蛋白覆盖。
3、观察、8天、12天、15天、创面愈合情况、创面肉芽组织生长情况，病理切片观察创面炎症、成纤维细胞数量。采用免疫组化检测涂药组和对照组的表皮生长因子、成纤维细胞生长因子以及神经生长因子。
实施例7
1、取10只平均体重为220g的糖尿病雄性大鼠，背部剃毛后消毒，用打孔器于大鼠背部脊柱两侧分别各打一孔(直径2cm)深及筋膜层。
2、采用同体对照，同一只大鼠背部一侧涂有活性胶原(Ⅰ型)水溶性凝胶，每次用量厚厚覆盖创面，用量大约4ml，另一次采用空白对照，一天换药6次，保证创面始终有胶原蛋白覆盖。
3、观察、8天、12天、15天、创面愈合情况、创面肉芽组织生长情况，病理切片观察创面炎症、成纤维细胞数量。采用免疫组化检测涂药组和对照组的表皮生长因子、成纤维细胞生长因子以及神经生长因子。
结果：1、同一只雄性糖尿病大鼠，涂有活性胶原(Ⅰ型)水溶性凝胶一侧伤口愈合较快，生长因子表达较多，病例切片显示涂药一侧组织胶原蛋白含量多，炎症反应较空白稍轻。说明活性胶原(Ⅰ型)水溶性凝胶在治疗糖尿病足有疗效。
2、在每次换药剂量不同，对创面愈合程度几乎与实施例4相同。
3、在每天换药次数不同，对创面愈合程度几乎与实施例4相同。

Claims (9)

  1. 一种治疗糖尿病足的水溶性凝胶，包括：
    Figure PCTCN2015082037-appb-100001
  2. 如权利要求1所述的水溶性凝胶，其中所述稀释液中生物低抗原性活性胶原(Ⅰ型)的浓度为0.1-0.5％，优选0.3-0.5％。
  3. 如权利要求1或2所述的水溶性凝胶，其中所述滋润剂为甘油；其用量优选4-4.5重量份。
  4. 如权利要求1-3任一项所述的水溶性凝胶，其中所述杀菌剂选自尼泊金甲酯或尼泊金丙酯中的一种或两种；其用量优选0.1-0.5重量份，更优选0.1-0.2重量份。
  5. 如权利要求1-4任一项所述的水溶性凝胶，其中所述辅料为水溶性硅油，优选为DC193；其用量优选0.1-0.8重量份，更优选0.2-0.6重量份。
  6. 如权利要求1-5任一项所述的水溶性凝胶，其中所述水溶性凝胶包括如下组分：
    Figure PCTCN2015082037-appb-100002
  7. 如权利要求1-6任一项所述的水溶性凝胶的制备方法，包括如下步骤：
    1)将生物低抗原性活性胶原(Ⅰ型)原液用水稀释；
    2)将滋润剂和杀菌剂与步骤1得到的稀释液混合搅拌；
    3)过滤；
    4)将辅料与步骤3得到的物料混合，搅拌均匀。
  8. 如权利要求7所述的方法，其中所述方法各步骤在无菌环境下进行。
  9. 权利要求1-6任一项所述的水溶性凝胶在制备治疗糖尿病足的药物中的应用。
PCT/CN2015/082037 2014-12-10 2015-06-23 一种治疗糖尿病足的水溶性凝胶 WO2016090892A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410755550.4A CN104474535A (zh) 2014-12-10 2014-12-10 一种治疗糖尿病足的水溶性凝胶
CN201410755550.4 2014-12-10

Publications (1)

Publication Number Publication Date
WO2016090892A1 true WO2016090892A1 (zh) 2016-06-16

Family

ID=52749234

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/082037 WO2016090892A1 (zh) 2014-12-10 2015-06-23 一种治疗糖尿病足的水溶性凝胶

Country Status (2)

Country Link
CN (1) CN104474535A (zh)
WO (1) WO2016090892A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3985019A4 (en) * 2020-04-24 2022-11-30 Nantong University RECOMBINANT HUMAN COLLAGEN AND PROCESS FOR PRODUCTION THEREOF
CN117582401A (zh) * 2023-12-07 2024-02-23 唐宁医药科技(济南)有限公司 一种糖尿病足凝胶及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104474535A (zh) * 2014-12-10 2015-04-01 成都新际生物活性胶原开发有限公司 一种治疗糖尿病足的水溶性凝胶
RU2619257C1 (ru) * 2016-09-14 2017-05-12 Константин Александрович Корейба Способ лечения дефектов мягких тканей у больных с синдромом диабетической стопы

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101851339A (zh) * 2010-05-19 2010-10-06 成都新际生物活性胶原开发有限公司 一种驴皮胶原的制备方法
CN102105177A (zh) * 2008-02-08 2011-06-22 路易斯·爱德华多·达·克鲁斯 治疗皮肤损伤的药物组合物、敷料和方法,用于制备所述敷料的中间组合物和方法,以及与胶原基质缔合的铈盐的用途
CN104474535A (zh) * 2014-12-10 2015-04-01 成都新际生物活性胶原开发有限公司 一种治疗糖尿病足的水溶性凝胶

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5079322B2 (ja) * 2003-04-11 2012-11-21 エコダイナミック・バイオラブ・インク 新規のコラーゲン製造方法
CN2701423Y (zh) * 2004-04-02 2005-05-25 富堡工业股份有限公司 创伤敷材结构
CN101721691B (zh) * 2008-11-04 2013-07-10 上海高科联合生物技术研发有限公司 一种用于感染创面治疗和修复的制剂及其制备方法
CN201473478U (zh) * 2009-06-19 2010-05-19 成都新际生物活性胶原开发有限公司 生物低抗原性活性胶原的生产设备
CN101829320B (zh) * 2010-05-20 2012-05-23 佟刚 一种胶原蛋白凝胶及其制备方法
CN103320485B (zh) * 2013-06-03 2015-12-23 王南平 一种医用级生物材料用鱼皮胶原的制备方法
CN103469365A (zh) * 2013-09-22 2013-12-25 山东颐诺生物科技有限公司 用于创伤修复的海藻酸-壳聚糖复合纤维及其制备方法
CN103908693B (zh) * 2014-04-15 2015-10-28 山东颐诺生物科技有限公司 一种仿生型海藻酸基复合抗菌敷料及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105177A (zh) * 2008-02-08 2011-06-22 路易斯·爱德华多·达·克鲁斯 治疗皮肤损伤的药物组合物、敷料和方法,用于制备所述敷料的中间组合物和方法,以及与胶原基质缔合的铈盐的用途
CN101851339A (zh) * 2010-05-19 2010-10-06 成都新际生物活性胶原开发有限公司 一种驴皮胶原的制备方法
CN104474535A (zh) * 2014-12-10 2015-04-01 成都新际生物活性胶原开发有限公司 一种治疗糖尿病足的水溶性凝胶

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3985019A4 (en) * 2020-04-24 2022-11-30 Nantong University RECOMBINANT HUMAN COLLAGEN AND PROCESS FOR PRODUCTION THEREOF
CN117582401A (zh) * 2023-12-07 2024-02-23 唐宁医药科技(济南)有限公司 一种糖尿病足凝胶及其制备方法
CN117582401B (zh) * 2023-12-07 2024-04-26 唐宁医药科技(济南)有限公司 一种糖尿病足凝胶及其制备方法

Also Published As

Publication number Publication date
CN104474535A (zh) 2015-04-01

Similar Documents

Publication Publication Date Title
JP6778219B2 (ja) 皮膚の炎症を抑制するイガイ接着タンパク質製品及びその適用
Frade et al. Management of diabetic skin wounds with a natural latex biomembrane
US20120231063A1 (en) Dressing comprising active components of centella asiatica and use of the same
WO2016090892A1 (zh) 一种治疗糖尿病足的水溶性凝胶
CA2762770A1 (en) Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing
KR20190126894A (ko) 치료법에서 사용하기 위한 보툴리눔 신경독소
CN113301910A (zh) 肽组分的皮肤更新和愈合混合物及其用途
CN114903981A (zh) 一种含有重组iii型胶原蛋白的创面修复配方
Carney et al. A pilot study of negative pressure therapy with autologous skin cell suspensions in a porcine model
CN105749333A (zh) 一种透明质酸医用敷料及其制备方法
CN103520708A (zh) 一种能促进创伤愈合、减少疤痕形成的组合物
CN104225577B (zh) 一种双疗程复合细胞生长因子水凝胶及制备方法及与应用
CN106562953B (zh) 羟基红花黄色素a在制备治疗糖尿病足溃疡的药物中的应用、药物及药物制备方法
CN114042032B (zh) 一种实现核酸皮肤递送的药物制剂及其制备方法和应用
CN101053657A (zh) 治疗顽固性皮肤溃疡的外用制剂
KR101820519B1 (ko) 설글리코타이드의 피부 상처 치유 촉진 용도, 및 이를 포함하는 외용제 조성물
CN109106979A (zh) 一种十三肽抗菌敷料及其制备方法
CN104667262B (zh) 重组牛碱性成纤维细胞生长因子外用溶液
CN112569346A (zh) 一种促进伤口愈合的水凝胶及其制备方法
CN113827706B (zh) Gip及其衍生肽作为制备皮肤创伤治疗药物中的应用
CN101057823A (zh) 一种具有抗衰老及美容作用的复合生物制剂
CN108635312A (zh) 一种植物精华疤痕修复液及其制备方法
CN114478695B (zh) 一类促进组织修复的新多肽及其应用
CN114621323B (zh) 一类具有皮肤修复作用的多肽化合物及其制备方法和应用
RU2794958C2 (ru) Композиция ранозаживляющего действия

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15866835

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 28/11/2017)

122 Ep: pct application non-entry in european phase

Ref document number: 15866835

Country of ref document: EP

Kind code of ref document: A1